“(3) A question that has been the subject of considerable research is whether the effect of fat on cancer is site-specific. Neither human nor animal studies are consistent in the association of fat intake with specific cancer sites.
(4) Another question that has been raised is whether the association of total fat intake to cancer risk is independently associated with energy intakes, or whether the association of fat with cancer risk is the result of the higher energy (caloric) intake normally associated with high fat intake. FDA has concluded that evidence from both animal and human studies indicates that total fat intake alone, independent of energy intake, is associated with cancer risk.
(b) Significance of the relationship between fat intake and risk of cancer. (1) Cancer is ranked as a leading cause of death in the United States. The overall economic costs of cancer, including direct health care costs and losses due to morbidity and mortality, are very high.” – CFR – Code of Federal Regulations Title 21
FDA Approved Drugs for Obesity
Trade or Brand Name | Generic Name (nonproprietary | Company | Type of Drug | Mechanism of Action | Approved | Notes |
---|---|---|---|---|---|---|
Alli, Xenical | Orlistat | GSK, Roche | lipase inhibitor | Inhibits fab absorption in the intestines | FDA – 2007 | Available OTC (Alli) & perscription (Xenical) |
Qsymia | Phentermine-Topiramate | VIVUS, Inc | sympathomimetic amine + anticonvulsant | Combination drug that suppresses appetite and has effects on metabolism | FDA – 2012 | |
Contrave | Naltrexone-Bupropion | Orexigen Therapeutics, Inc. | antidepressant + opioid antogonist | Combination drug affects the CNS to reduce hunger | FDA – 2014 | |
Saxenda | Liraglutide | Novo Nordisk | injectable GLP-1 receptor agonist | GLP-1 receptor agonist | FDA – 2020 | |
Wegovy | Semaglutide | Novo Nordisk | injectable GLP-1 receptor agonist | GLP-1 receptor agonist | FDA -2012 | |
Zepbound | Tirzepatide | Eli Lilly | injectable GLP-1 and GIP receptors dual agonist | dual GLP-1 and GIP receptors agonist | FDA – 2023 |